Establishment of 株式会社フェルゼンファーマ
First written in FY2017-Q3. 22 of 25 entries say "Advanced", first in FY2018. Latest entry: 2026-08-07.
No other company in this theme has enough history to compare yet.
- 2026-08-07AdvancedEarnings presentation materials
「2026年6月に『ビラスチンOD錠』を発売」
フェルゼンファーマを含む医薬品製造販売事業で、新たな取扱品目の発売実績を示した。 - FY2026-H1AdvancedAnnual report
「The pharmaceutical manufacturing and sales division worked to develop new business partners, resulting in steady growth in the number of customer stores, which reached 7,823, an increase of 2,123 stores from the end of the same period of the previous year. As of 30 September 2025, it was selling 52 active ingredients across 120 products, including 6 active ingredients across 11 products subject to shipment adjustments.」
In the pharmaceutical manufacturing and marketing business centered on フェルゼンファーマ, the number of trading stores expanded to 7,823 through the development of new business partners. - FY2025AdvancedAnnual report
「As of 31 March 2025, the pharmaceutical manufacturing and marketing division was selling 52 active ingredients in 120 products (3 active ingredients in 6 products were subject to shipment adjustments).」
The number of generic-drug products sold expanded from 49 active ingredients in 113 products at the end of the previous fiscal year to 52 active ingredients in 120 products. Products subject to shipment adjustments continued to be reported. - FY2025-H1AdvancedAnnual report
「As of 30 September 2024, 49 active ingredients in 113 products were being sold (3 active ingredients in 6 products were subject to shipment adjustments). The number of new trading stores progressed steadily during the six-month consolidated period, and as of 30 September 2024, the number of trading stores was 5,700, an increase of 1,806 from the end of the same period of the previous year.」
The number of generic-drug products sold and trading stores expanded, advancing the pharmaceutical manufacturing and marketing business. At the same time, products subject to shipment adjustments were also disclosed. - FY2024-Q2AdvancedAnnual report
「The pharmaceutical manufacturing and sales division was selling 47 active ingredients across 98 products as of 30 September 2023. Although orders for some products had been suspended due to shipment adjustments, the number of new customer stores during the second quarter progressed steadily, reaching 3,894 as of 30 September 2023, an increase of 663 stores year on year.」
In the generic-drug business centered on フェルゼンファーマ, the number of products sold expanded to 47 active ingredients in 98 products, and the number of trading stores reached 3,894. - FY2024-Q1AdvancedAnnual report
「As of 30 June 2023, the pharmaceutical manufacturing and marketing division was selling 46 active ingredients in 96 products. Although orders for some products had been suspended due to shipment adjustments, the number of new trading stores increased by 345 during the first quarter, bringing the number of trading stores as of 30 June 2023 to 3,642, an increase of 727 from the same period of the previous year.」
The scale of generic-drug sales expanded to 46 active ingredients in 96 products, and the number of trading stores reached 3,642. The suspension of orders for some products due to shipment adjustments was also disclosed. - FY2023-Q3AdvancedAnnual report
「The pharmaceutical manufacturing and sales division was selling 44 active ingredients across 90 products as of 31 December 2022. In addition to the Group's pharmacies, the number of stores with which it did business reached 2,042 general member pharmacies, an increase of 344 stores from the end of the previous consolidated fiscal year.」
The number of generic-drug products sold expanded from 41 active ingredients in 82 products at the end of the previous fiscal year to 44 active ingredients in 90 products, and the number of trading stores also increased. - FY2022AdvancedAnnual report
「During the consolidated fiscal year, 7 active ingredients in 14 products were newly launched. As of 31 March 2022, 41 active ingredients in 82 products were being sold.」
New generic-drug launches and product expansion continued, bringing the scale of sales to 41 active ingredients in 82 products. - FY2022-Q3AdvancedAnnual report
「The pharmaceutical manufacturing and sales division launched 7 active ingredients across 12 products during the first 9 months of the fiscal year and, as of 31 December 2021, was selling 41 active ingredients across 80 products.」
New generic-drug launches and product-lineup expansion continued, and the manufacturing and marketing business centered on フェルゼンファーマ progressed to the stage of selling 41 active ingredients in 80 products. - FY2022-Q2AdvancedAnnual report
「The pharmaceutical manufacturing and sales division launched 5 active ingredients across 9 products during the first 6 months of the fiscal year and, as of 30 September 2021, was selling 39 active ingredients across 77 products.」
New generic-drug launches and product-lineup expansion continued, bringing the number of products sold to 39 active ingredients in 77 products. - FY2022-Q1AdvancedAnnual report
「The pharmaceutical manufacturing and sales division launched 3 active ingredients across 6 products in June 2021 and, as of 30 June 2021, was selling 37 active ingredients across 74 products.」
New generic-drug launches and product expansion continued, bringing the scale of sales to 37 active ingredients in 74 products. - FY2021AdvancedAnnual report
「The pharmaceutical manufacturing and sales division is working to ensure a stable supply of high-quality, low-cost generic drugs, and sales are growing steadily, including following the launch of 11 active ingredients across 17 products during the fiscal year. As of 31 March 2021, it was selling 34 active ingredients across 68 products and will continue to expand its product lineup further.」
During the period, 11 active ingredients in 17 products were launched, increasing the number of products sold to 34 active ingredients in 68 products. - FY2021-Q3AdvancedAnnual report
「The pharmaceutical manufacturing and marketing division is working to ensure a stable supply of high-quality, low-cost generic drugs and launched pregabalin orally disintegrating tablets, a product with a large market, in December 2020. As of 31 December 2020, it was selling 33 active ingredients in 66 products and plans to further expand its product lineup.」
A new product with a large market was launched, and the scale of sales expanded to 33 active ingredients in 66 products. The product lineup in the generic-drug manufacturing and marketing business continues to expand. - FY2021-Q2AdvancedAnnual report
「The pharmaceutical manufacturing and marketing division worked to ensure a stable supply of high-quality, low-cost generic drugs and achieved a semiannual profit for the first time since the business began. As of 30 September 2020, it was selling 32 active ingredients in 63 products.」
The scale of generic-drug sales expanded to 32 active ingredients in 63 products, and the pharmaceutical manufacturing and marketing division achieved a semiannual profit for the first time since the business began. - FY2021-Q1AdvancedAnnual report
「The pharmaceutical manufacturing and sales division continues to work to ensure a stable supply of high-quality, low-cost generic drugs. As of 30 June 2020, it was selling 29 active ingredients across 60 products, and the number of stores handling products at general member pharmacies in the pharmaceutical network had reached 707.」
The number of generic-drug products sold increased from the previously reported 23 active ingredients in 51 products to 29 active ingredients in 60 products, advancing the pharmaceutical manufacturing and marketing business. - FY2020-Q3AdvancedAnnual report
「The pharmaceutical manufacturing and sales division is working to ensure a stable supply of high-quality, low-cost generic drugs and, as of 31 December 2019, was selling 23 active ingredients across 51 products.」
The number of generic-drug products sold increased from 17 active ingredients in 34 products at the end of March 2019 and 20 active ingredients in 45 products at the end of September to 23 active ingredients in 51 products. - FY2020-Q2AdvancedAnnual report
「The pharmaceutical manufacturing and sales division is working to ensure a stable supply of high-quality, low-cost generic drugs and, as of 30 September 2019, was selling 20 active ingredients across 45 products.」
The number of generic-drug products sold, centered on フェルゼンファーマ, increased from 17 active ingredients in 34 products at the end of March 2019 to 20 active ingredients in 45 products. - FY2020-Q1AdvancedAnnual report
「The pharmaceutical manufacturing and sales division is working to ensure a stable supply of high-quality, low-cost generic drugs and, as of 30 June 2019, was selling 18 active ingredients across 39 products.」
The number of generic-drug products sold increased from 17 active ingredients in 34 products at the end of March 2019 to 18 active ingredients in 39 products, continuing the expansion of the product lineup after sales began. - FY2019AdvancedAnnual report
「As of 31 March 2019, 株式会社フェルゼンファーマ, which operates a pharmaceutical manufacturing and marketing business, was selling 17 active ingredients in 34 products and working to ensure a stable supply of high-quality, low-cost generic drugs.」
The number of generic-drug products sold increased from 16 active ingredients in 32 products at the end of December 2018 to 17 active ingredients in 34 products. - FY2019-Q3AdvancedAnnual report
「As of 31 December 2018, 株式会社フェルゼンファーマ, which operates a pharmaceutical manufacturing and marketing business, was selling 16 active ingredients in 32 products and working to ensure a stable supply of high-quality, low-cost generic drugs.」
After the launch of generic-drug sales, the business progressed to selling 16 active ingredients in 32 products as of the end of December 2018, and efforts to ensure a stable supply continued. - FY2019-Q2RestatedAnnual report
「株式会社フェルゼンファーマ, which operates a pharmaceutical manufacturing and marketing business, began selling generic drugs in June 2018 and is working to ensure a stable supply of high-quality, low-cost generic drugs.」
Efforts to sell generic drugs and ensure a stable supply through フェルゼンファーマ continue. - FY2019-Q1AdvancedAnnual report
「In June 2018, 株式会社フェルゼンファーマ, which operates a pharmaceutical manufacturing and marketing business, began selling generic drugs.」
フェルゼンファーマ progressed from the establishment and business-alliance stage to the launch of generic-drug sales. - FY2018AdvancedAnnual report
「February 2018: 株式会社フェルゼンファーマ entered into a business alliance with Daito Pharmaceutical Co.,Ltd.」
フェルゼンファーマ entered into a business alliance with Daito and began selling generic drugs in June 2018. Its business development after establishment progressed to the alliance and product-launch stage. - FY2017RestatedAnnual report
「We established 株式会社フェルゼンファーマ on 20 September 2016.」
The establishment of フェルゼンファーマ and its status as a consolidated subsidiary continue to be disclosed. - FY2017-Q3First statedAnnual report
「We established 株式会社フェルゼンファーマ on 20 September 2016.」
Established on 20 September 2016 and classified as an Other business as a consolidated subsidiary.